Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | RET | P07949 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20071282 | 0.81 | SMN1; SMN2 (0.47) | SMN1; SMN2POLBNPSR1L3MBTL1RET | |
| SCHEMBL22031234 | 0.79 | SMN1; SMN2 (0.46) | SMN1; SMN2POLBNPSR1L3MBTL1RET | |
| SCHEMBL20148596 | 0.79 | SMN1; SMN2 (0.46) | SMN1; SMN2POLBNPSR1L3MBTL1RET | |
| SCHEMBL22030758 | 0.76 | CYP2C19 (0.35) | RETKDM4ECYP2C19ALDH1A1 | |
| SCHEMBL22031233 | 0.75 | SMN1; SMN2 (0.42) | SMN1; SMN2POLBNPSR1L3MBTL1RET | |
| SCHEMBL17470614 | 0.74 | SMN1; SMN2 (0.50) | SMN1; SMN2POLBNPSR1L3MBTL1KDM4E | |
| SCHEMBL25569731 | 0.74 | — | — | |
| SCHEMBL14211286 | 0.74 | SMN1; SMN2 (0.43) | SMN1; SMN2POLBNPSR1L3MBTL1KDM4E | |
| SCHEMBL19350472 | 0.69 | SMN1; SMN2 (0.46) | SMN1; SMN2POLBNPSR1L3MBTL1KDM4E | |
| SCHEMBL18782764 | 0.69 | PRKCA (0.35) | SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10172851-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2019-01-08 | — | — | US | disclosed |
| US-20180133213-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2018-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10172851-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | RET, ROR1, BRAF | SMN1; SMN2 833/4885POLB 3678/4885NPSR1 2516/4885 |
| US-20180133213-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | RET, ROR1, BRAF | SMN1; SMN2 833/4885POLB 3678/4885NPSR1 2516/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.